Cover Image
市場調查報告書

全身性硬皮症(皮膚硬化症):開發平台分析

Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 213039
出版日期 內容資訊 英文 184 Pages
訂單完成後即時交付
價格
Back to Top
全身性硬皮症(皮膚硬化症):開發平台分析 Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2016
出版日期: 2016年07月27日 內容資訊: 英文 184 Pages
簡介

所謂皮膚硬化症是皮膚和結締組織硬化的難治之症之一。主要的症狀有肌肉痛和關節痛,腫脹(膿腫),指尖出現潰瘍,腹部膨脹,腹瀉·便秘等。主要的治療藥有抗生素和止痛藥,免疫抑制劑等。

本報告提供全球各國的全身性硬皮症治療用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

全身性硬皮症概要

治療藥的開發

  • 全身性硬皮症開發中產品:概要
  • 全身性硬皮症開發中產品:比較分析

各企業正在開發的全身性硬皮症治療藥

大學/研究機關研究中的全身性硬皮症治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 不明確的階段有的產品

全身性硬皮症治療藥:開發中的產品一覽(各企業)

全身性硬皮症治療藥:研究中的產品一覽(大學/研究機關別)

全身性硬皮症開發治療藥的企業

  • Allergan Plc
  • Angion Biomedica Corp.
  • arGentis Pharmaceuticals, LLC
  • Bayer AG
  • BioLineRx, Ltd.
  • BiOrion Technologies B.V.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Corbus pharmaceuticals, Inc.
  • CSL Limited
  • Daval International Limited
  • Digna Biotech, S.L.
  • F. Hoffmann-La Roche Ltd.
  • Fibrocell Science, Inc.
  • GenKyoTex S.A.
  • GlaxoSmithKline Plc
  • iBio, Inc.
  • Inventiva SAS
  • Kadmon Corporation, LLC
  • miRagen Therapeutics, Inc.
  • Peptinov SAS
  • Ribomic Inc.
  • Stratatech Corporation
  • Vida Therapeutics Inc.
  • VivaCell Biotechnology Espana S.L.

全身性硬皮症:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • abatacept
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • acALY-18
  • acetylcysteine
  • Aimspro
  • ANG-3070
  • ARG-201
  • belimumab
  • BL-1110
  • BOT-191
  • C-82
  • Cell Therapy for Dermatology and Immunology
  • disitertide
  • factor XIII (human)
  • FCX-013
  • GKT-831
  • GSK-2330811
  • IBIOCFB-03
  • IVA-337
  • JBT-101
  • KD-025
  • MGN-4220
  • nintedanib
  • Oligonucleotide for Scleroderma
  • onabotulinumtoxin A
  • PAT-048
  • PDX-002
  • PPV-06
  • RBM-006
  • riociguat
  • Small Molecule to Inhibit NFkB for Immunology and Oncology
  • Stem Cell Therapy for Crohns Disease, Systemic Sclerosis and Multiple Sclerosis
  • Synthetic Peptides to Inhibit TCR for Autoimmune Disorders and Dermatitis
  • tocilizumab
  • VCE-0048
  • VEDA-1209
  • VTI-1000 Series

全身性硬皮症治療藥:開發中產品的最新趨勢

全身性硬皮症治療藥:開發暫停的產品

全身性硬皮症治療藥:開發中止的產品

全身性硬皮症相關產品的開發的里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8302IDB

Summary

Global Markets Direct's, 'Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2016', provides an overview of the Systemic Sclerosis (Scleroderma) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Systemic Sclerosis (Scleroderma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Systemic Sclerosis (Scleroderma) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Systemic Sclerosis (Scleroderma)
  • The report reviews pipeline therapeutics for Systemic Sclerosis (Scleroderma) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Systemic Sclerosis (Scleroderma) therapeutics and enlists all their major and minor projects
  • The report assesses Systemic Sclerosis (Scleroderma) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Systemic Sclerosis (Scleroderma)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Systemic Sclerosis (Scleroderma)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Systemic Sclerosis (Scleroderma) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Systemic Sclerosis (Scleroderma) Overview
  • Therapeutics Development
    • Pipeline Products for Systemic Sclerosis (Scleroderma) - Overview
    • Pipeline Products for Systemic Sclerosis (Scleroderma) - Comparative Analysis
  • Systemic Sclerosis (Scleroderma) - Therapeutics under Development by Companies
  • Systemic Sclerosis (Scleroderma) - Therapeutics under Investigation by Universities/Institutes
  • Systemic Sclerosis (Scleroderma) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Systemic Sclerosis (Scleroderma) - Products under Development by Companies
  • Systemic Sclerosis (Scleroderma) - Products under Investigation by Universities/Institutes
  • Systemic Sclerosis (Scleroderma) - Companies Involved in Therapeutics Development
    • Allergan Plc
    • Angion Biomedica Corp.
    • Antitope Limited
    • Bayer AG
    • BioLineRx, Ltd.
    • BiOrion Technologies B.V.
    • Boehringer Ingelheim GmbH
    • Bristol-Myers Squibb Company
    • Covis Pharmaceuticals, Inc.
    • CSL Limited
    • Cumberland Pharmaceuticals, Inc.
    • Digna Biotech, S.L.
    • F. Hoffmann-La Roche Ltd.
    • Fibrocell Science, Inc.
    • GenKyoTex S.A.
    • Gilead Sciences, Inc.
    • GlaxoSmithKline Plc
    • iBio, Inc.
    • Inventiva
    • Kadmon Corporation, LLC
    • MedImmune, LLC
    • miRagen Therapeutics, Inc.
    • PDX Pharmaceuticals LLC
    • Peptinov SAS
    • ProMetic Life Sciences Inc.
    • Ribomic Inc.
    • Sanofi
    • Stemline Therapeutics, Inc.
    • Stratatech Corporation
    • Vida Therapeutics Inc.
    • VivaCell Biotechnology Espana S.L.
  • Systemic Sclerosis (Scleroderma) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • abatacept - Drug Profile
    • acALY-18 - Drug Profile
    • acetylcysteine - Drug Profile
    • ambrisentan - Drug Profile
    • ANG-3070 - Drug Profile
    • belimumab - Drug Profile
    • BL-1110 - Drug Profile
    • BOT-191 - Drug Profile
    • C-1889 - Drug Profile
    • C-82 - Drug Profile
    • Cell Therapy for Dermatology and Immunology - Drug Profile
    • CM-101 - Drug Profile
    • disitertide - Drug Profile
    • factor XIII (human) - Drug Profile
    • FCX-013 - Drug Profile
    • GKT-831 - Drug Profile
    • GSK-2330811 - Drug Profile
    • IBIOCFB-03 - Drug Profile
    • ifetroban sodium - Drug Profile
    • IVA-337 - Drug Profile
    • JBT-101 - Drug Profile
    • KD-025 - Drug Profile
    • M-10 - Drug Profile
    • MEDI-7734 - Drug Profile
    • MGN-4220 - Drug Profile
    • Monoclonal Antibodies to Inhibit IL-3RA for Autoimmune Disorders - Drug Profile
    • nintedanib - Drug Profile
    • nitroglycerin - Drug Profile
    • Oligonucleotide for Scleroderma - Drug Profile
    • onabotulinumtoxin A - Drug Profile
    • PAT-048 - Drug Profile
    • PBI-4050 - Drug Profile
    • PDX-002 - Drug Profile
    • PPV-06 - Drug Profile
    • RBM-006 - Drug Profile
    • riociguat - Drug Profile
    • RP-182 - Drug Profile
    • SAR-100842 - Drug Profile
    • SAR-317461 - Drug Profile
    • Small Molecule to Inhibit NFkB for Immunology and Oncology - Drug Profile
    • SRI-35241 - Drug Profile
    • Synthetic Peptides to Inhibit TCR for Autoimmune Disorders and Dermatitis - Drug Profile
    • terguride - Drug Profile
    • tocilizumab - Drug Profile
    • VCE-0048 - Drug Profile
    • VEDA-1209 - Drug Profile
    • VTI-1000 Series - Drug Profile
  • Systemic Sclerosis (Scleroderma) - Dormant Projects
  • Systemic Sclerosis (Scleroderma) - Discontinued Products
  • Systemic Sclerosis (Scleroderma) - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Systemic Sclerosis (Scleroderma), H2 2016
  • Number of Products under Development for Systemic Sclerosis (Scleroderma) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Systemic Sclerosis (Scleroderma) - Pipeline by Allergan Plc, H2 2016
  • Systemic Sclerosis (Scleroderma) - Pipeline by Angion Biomedica Corp., H2 2016
  • Systemic Sclerosis (Scleroderma) - Pipeline by Antitope Limited, H2 2016
  • Systemic Sclerosis (Scleroderma) - Pipeline by Bayer AG, H2 2016
  • Systemic Sclerosis (Scleroderma) - Pipeline by BioLineRx, Ltd., H2 2016
  • Systemic Sclerosis (Scleroderma) - Pipeline by BiOrion Technologies B.V., H2 2016
  • Systemic Sclerosis (Scleroderma) - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Systemic Sclerosis (Scleroderma) - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Systemic Sclerosis (Scleroderma) - Pipeline by Covis Pharmaceuticals, Inc., H2 2016
  • Systemic Sclerosis (Scleroderma) - Pipeline by CSL Limited, H2 2016
  • Systemic Sclerosis (Scleroderma) - Pipeline by Cumberland Pharmaceuticals, Inc., H2 2016
  • Systemic Sclerosis (Scleroderma) - Pipeline by Digna Biotech, S.L., H2 2016
  • Systemic Sclerosis (Scleroderma) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Systemic Sclerosis (Scleroderma) - Pipeline by Fibrocell Science, Inc., H2 2016
  • Systemic Sclerosis (Scleroderma) - Pipeline by GenKyoTex S.A., H2 2016
  • Systemic Sclerosis (Scleroderma) - Pipeline by Gilead Sciences, Inc., H2 2016
  • Systemic Sclerosis (Scleroderma) - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Systemic Sclerosis (Scleroderma) - Pipeline by iBio, Inc., H2 2016
  • Systemic Sclerosis (Scleroderma) - Pipeline by Inventiva, H2 2016
  • Systemic Sclerosis (Scleroderma) - Pipeline by Kadmon Corporation, LLC, H2 2016
  • Systemic Sclerosis (Scleroderma) - Pipeline by MedImmune, LLC, H2 2016
  • Systemic Sclerosis (Scleroderma) - Pipeline by miRagen Therapeutics, Inc., H2 2016
  • Systemic Sclerosis (Scleroderma) - Pipeline by PDX Pharmaceuticals LLC, H2 2016
  • Systemic Sclerosis (Scleroderma) - Pipeline by Peptinov SAS, H2 2016
  • Systemic Sclerosis (Scleroderma) - Pipeline by ProMetic Life Sciences Inc., H2 2016
  • Systemic Sclerosis (Scleroderma) - Pipeline by Ribomic Inc., H2 2016
  • Systemic Sclerosis (Scleroderma) - Pipeline by Sanofi, H2 2016
  • Systemic Sclerosis (Scleroderma) - Pipeline by Stemline Therapeutics, Inc., H2 2016
  • Systemic Sclerosis (Scleroderma) - Pipeline by Stratatech Corporation, H2 2016
  • Systemic Sclerosis (Scleroderma) - Pipeline by Vida Therapeutics Inc., H2 2016
  • Systemic Sclerosis (Scleroderma) - Pipeline by VivaCell Biotechnology Espana S.L., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Systemic Sclerosis (Scleroderma) - Dormant Projects, H2 2016
  • Systemic Sclerosis (Scleroderma) - Dormant Projects (Contd..1), H2 2016
  • Systemic Sclerosis (Scleroderma) - Dormant Projects (Contd..2), H2 2016
  • Systemic Sclerosis (Scleroderma) - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Systemic Sclerosis (Scleroderma), H2 2016
  • Number of Products under Development for Systemic Sclerosis (Scleroderma) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top